Covid-19 roundup: Fred Hutch cuts down further on lab work, Roche joins Regeneron and Sanofi in IL-6 trials, China orders a vaccine effort
We’re now more than three-and a-half months into the outbreak. That window means we may soon get a glimpse of what works against Covid-19, but in the US the impact on all other research may be just beginning.
→ When Seattle emerged as the first major metro area hit severely by the coronavirus, The Fred Hutchinson Cancer Research Center was one of the first major scientific institutions to send non-essential personnel home. Now they’re taking further steps. While emphasizing that they are not closing, the center asked labs at its main Seattle campus to limit their on-site personnel to an “absolute minimum” by yesterday and transfer “almost all” on-site work to remote work as early as Monday. They said it would likely last through April 24, if not longer.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 109,500+ biopharma pros reading Endpoints daily — and it's free.